Poseida Therapeutics Inc (Nadsaq: PSTX), a US-based clinical-stage biopharmaceutical company, announced on Monday that it has named Cynthia Collins as its new director effective 23 July 2021.

Collins has served as the CEO of Editas Medicine, CEO of Human Longevity Inc; the CEO/GM of the Cell Therapy and Lab Business of General Electric's Healthcare Life Sciences; and the CEO of Clarient Diagnostics Inc. She has also held leadership roles which include president and CEO of GenVec Inc and group vice president, Cellular Analysis Business of Beckman Coulter with responsibility for its Haematology, Flow Cytometry, and Haemostasis businesses. She has also served as president and CEO of Sequoia Pharmaceuticals Inc. She is serving as a member of the boards of directors at DermTech Inc, Certara, Biocare Medical LLC, and Triumvira Immunologics Inc and earlier served on the boards for the ARM Foundation for Cell and Gene Medicine and Alliance for Regenerative Medicine.

Collins has her BS degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business.